- Home
- DNLI vs TLX Comparison
DNLI vs TLX Comparison
Compare DNLI & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DNLI | TLX |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.9B |
| IPO Year | 2017 | 2024 |
Fundamental Metrics
Financial Performance| Metric | DNLI | TLX |
|---|---|---|
| Price | $24.92 | $11.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 4 |
| Target Price | ★ $34.33 | $21.13 |
| AVG Volume (30 Days) | ★ 1.3M | 91.4K |
| Earning Date | 05-06-2026 | 08-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $408.85 | N/A |
| P/E Ratio | ★ N/A | $150.33 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.58 | $6.28 |
| 52 Week High | $27.30 | $12.58 |
Technical Indicators
Market Signals| Indicator | DNLI | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 53.25 | 50.89 |
| Support Level | $22.32 | $10.12 |
| Resistance Level | $25.74 | $11.48 |
| Average True Range (ATR) | 0.83 | 0.21 |
| MACD | 0.03 | 0.06 |
| Stochastic Oscillator | 62.75 | 51.29 |
Price Performance
Historical ComparisonAbout DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
About TLX Telix Pharmaceuticals Limited American Depositary Shares
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.